The Delaware HIV Consortium is pleased to announce that it has been awarded a grant from Gilead Sciences for a new Pre- Exposure Prophylaxis (PrEP) education program.  Called “Delaware PrEP Community Education Initiative,” the program will pull together key stakeholders, State officials, and the medical community to develop a plan to increase education of PrEP through targeted outreach to individuals at high risk and to identify healthcare providers who are willing to learn more about PrEP as a tool for HIV prevention and awareness.  The PrEP initiative will culminate in a statewide summit to be held in Summer 2016.  
Recently, PrEP was added to the revised National HIV/AIDS Strategy (2015) as a tool in preventing HIV infection.  PrEP is a way for people who don’t have HIV to prevent HIV infection by taking one pill every day. The pill contains two medicines that are also used to treat HIV. If you take PrEP and are exposed to HIV through sex or injection drug use, these medicines can work to keep the virus from taking hold in your body.  Along with other prevention methods like condoms, PrEP can offer good protection against HIV if taken every day.